Clinical trial
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
NCT00349193 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00349193 |
|---|---|
| Title | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod |
| Official title | A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis |
| Intervention type | Drug, Other |
| Interventions | laquinimod 0.3, laquinimod 0.6, Placebo |
| Enrollment | 306 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jul 6, 2006 |
| Last update posted | Apr 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: